BTOG 2019 | DDR proteins emerging as biomarkers and targets in lung cancer: the case of hSSB1
Kenneth O'Byrne
Presenting an array of work from his group in Brisbane on DNA damage repair proteins that are emerging as biomarkers and targets in lung cancer, Ken O’Byrne, MD, of the Princess Alexandra Hospital, Brisbane, Queensland, Australia, spoke to us about the context and application of this research. Prof. O’Byrne highlights hSSB1, discovered by his research partner Prof. Derek Richard, a highly conserved and important protein in the DNA damage repair process, and goes on to discuss the upcoming translation of this work into a clinical trial. This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference, held in Dublin, Ireland.
Related videos
2:03
TKIs to treat EGFRm-positive NSCLC
Marina Garassino
1:16
The promise of stereotactic radiotherapy for oligometastases
Françoise Mornex
1:50
Prof. Kelly’s overview of the RECaN project
Daniel Kelly
1:03
Managing oligometastatic NSCLC with thoracic irradiation
Françoise Mornex
2:06
Afatinib for advanced EGFRm-positive NSCLC
Antonio Passaro
